Global Literature Review On The Incidence Of Nd:Yag Laser Capsulotomy Post-Cataract Surgery In Eyes Implanted With The Clareon Intraocular Lens Implanted Eye

The improvements in surgical technique has made cataract surgery an increasingly safe procedure,  posterior capsule opacification (PCO), however, remains the most common complication post-cataract surgery. PCO development has been associated with IOL design, IOL biomaterial, and other factors. Nd:YAG laser capsulotomy is used to treat clinically significant PCO.

Europe, Australia, Japan, Korea, and India 

An electronic search of MEDLINE, Embase, Cochrane Library, European and American Society for Cataract and Refractive Surgeons congress databases for articles published between Nov-01-2017 to Dec-31-2022 were included. Incidence of PCO requiring Nd: YAG post Clareon IOL implantation and the weighted average of Nd:YAG capsulotomy incidence was reported. 

Eight clinical trials encompassing Europe, Australia, Japan, Korea, and India reporting the incidence of PCO requiring Nd: YAG were identified. Nd: YAG incidence of 0.0% was reported in studies in Australia (N=40), Spain (N=60), Korea (N=126), and India (N=151).  In Japan, a 5.0% incidence rate was reported. In Europe, at one year, a 0.9% incidence was reported in the 1st eye (N=215) and 0.0% in the 2nd eye (N=209), at two years, a  1.4%  incidence was reported in the 1st eye (N=215) and 1.9% in the 2nd eye (N=209), at three years, a 3.3% incidence was reported in the 1st eye (N=215) and 6.7% in the 2nd eye (N=209). The weighted average YAG capsulotomy incidence at 1 year was 0.74%, 2 years was 1.47%, and at three years was 2.20%.

Global clinical studies have demonstrated that Clareon IOL biomaterial and its squared edge design protect against PCO with low incidence rates of Nd: YAG capsulotomy.